Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baxdrostat thorough QT study in healthy volunteers
NCT06194032Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of baxdrostat in resistant hypertension (RH) (4 arms), sponsored by AstraZeneca. Primary endpoint: Placebo corrected change from baseline in QTcF at Day 3. Started Feb 2024; status: completed.
02
Drugs
baxdrostat
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on NCT06194032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06194032.